50 of the Top 250 law firms use our Products every day
|
EXHIBIT 10.2
September 19, 2006
Re: Collaboration and License Agreement dated as
of August 1, 2006 by and between POZEN INC. and Astrazeneca AB (the
"Collaboration Agreement")
Dear Denise:
This letter sets forth the understanding between
POZEN INC. ("POZEN") and Astrazeneca AB ("Astrazeneca") with regard
to the matters set forth below and in connection with the
Collaboration Agreement. Any capitalized terms not otherwise
defined herein shall have the meaning given such term in the
Collaboration Agreement. POZEN and Astrazeneca herein are
collectively referred to as the Parties.
1. In accordance
with Section 12.1 of the Collaboration Agreement, the Effective
Date of the Collaboration Agreement is September 7,
2006.
2. The Parties have
attached hereto final versions of Schedule 10.1 and Schedule 10.7,
which shall be incorporated by this reference and made part of the
Collaboration Agreement.
3. The Parties agree
that a final schedule of Formulation Development Activities and a
Formulation Budget pursuant to Section 6.1.4 of the Collaboration
Agreement shall be agreed by the Parties as soon as reasonably
practicable but not later than *****.
4. This letter is
being executed pursuant to the terms of Section 15.6 of the
Collaboration Agreement
|
